| First Author | Liu YJ | Year | 2023 |
| Journal | Proc Natl Acad Sci U S A | Volume | 120 |
| Issue | 8 | Pages | e2210643120 |
| PubMed ID | 36795751 | Mgi Jnum | J:339361 |
| Mgi Id | MGI:7519991 | Doi | 10.1073/pnas.2210643120 |
| Citation | Liu YJ, et al. (2023) Cspg4(high) microglia contribute to microgliosis during neurodegeneration. Proc Natl Acad Sci U S A 120(8):e2210643120 |
| abstractText | Microglia play a critical role in the pathogenic process of neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD). Upon pathological stimulation, microglia are converted from a surveillant to an overactivated phenotype. However, the molecular characters of proliferating microglia and their contributions to the pathogenesis of neurodegeneration remain unclear. Here, we identify chondroitin sulfate proteoglycan 4 (Cspg4, also known as neural/glial antigen 2)-expressing microglia as a specific subset of microglia with proliferative capability during neurodegeneration. We found that the percentage of Cspg4(+) microglia was increased in mouse models of PD. The transcriptomic analysis of Cspg4(+) microglia revealed that the subcluster Cspg4(high) microglia displayed a unique transcriptomic signature, which was characterized by the enrichment of orthologous cell cycle genes and a lower expression of genes responsible for neuroinflammation and phagocytosis. Their gene signatures were also distinct from that of known disease-associated microglia. The proliferation of quiescent Cspg4(high) microglia was evoked by pathological alpha-synuclein. Following the transplantation in the adult brain with the depletion of endogenous microglia, Cspg4(high) microglia grafts showed higher survival rates than their Cspg4(-) counterparts. Consistently, Cspg4(high) microglia were detected in the brain of AD patients and displayed the expansion in animal models of AD. These findings suggest that Cspg4(high) microglia are one of the origins of microgliosis during neurodegeneration and may open up a avenue for the treatment of neurodegenerative diseases. |
